



# Hyaluronic Acid Prevent Further Cartilage Damage of Osteoarthritis Based on Expression of Collagen Type II and Collagen Type X

Mohamad Hidayat<sup>®</sup>, Krisna Yuarno Phatama\*<sup>®</sup>, Tofan Margaret Dwi Saputra, Domy Pradana Putra<sup>®</sup>, Lasa Dhakka Siahaan<sup>®</sup>, Muhammad Alwy Sugiarto<sup>10</sup>, Ananto Satya Pradana<sup>10</sup>, Edi Mustamsir<sup>10</sup>

Department of Orthopedics and Traumatology, Faculty of Medicine Universitas Brawijava, RSUD Dr. Saiful Anwar, Malang, East Java, Indonesia

#### Abstract

Edited by: Ksenija Bogoeva-Kostovska Citation: Hidayat M, Phatama KY, Saputra TMD, Putra DP, Siahaan LD, Sugiarto MA, Pradana AS, Mustamsir E. Hyaluronic Acid Prevent Further Cartilage Damage of Osteoarthritis Based on Expression of Collagen Type II and Collagen Type X. Open Access Maced J Med Sci. 2022 Mar 10; 10(B):757-763. https://doi.org/10.3889/oamjms.2022.8748 Kauverde: Knee osteoarthritis: Hyaluropic acid: Tyne II Keywords: Knee osteoarthritis; Hyaluronic acid; Type II collagen; Type X collager \*Correspondence: Krisna Yuarno Phatama, Department \*Correspondence: Krisna Yuarno Phatama, Department of Orthopaedic and Traumatology, Faculty of Medicine Universitas Brawijaya, RSUD Dr. Saiful Anwar, Jl. Jaksa Agung Suprapto 2, Malang - 65111, East Java, Indonesia. E-mail: krisnayuarno@ub.ac.id Received: 24-Jan-2022 Revised: 20-Feb-2022 Revised: 20-F69-2022 Accepted: 28-F69-2022 Copyright: © 2022 Mohamad Hidayat, Krisna Yuarno Phatama, Tofan Margaret Dwi Saputra, Domy Pradana Putra, Lasa Dhakka Siahaan, Muhammad Alwy Sugiarto, Ananto Satya Pradana, Edi Mustamsir Funding: This research did not receive any financia support Competing Interests: The authors have declared that no

Competing interests into database into a competing interests exist competing interests exist Open Access: This is an open-access article distributed under the terms of the Creative Commons Artifibution-NonCommercial 4.0 International License (CC BY-NC 4.0)

#### BACKGROUND: Osteoarthritis (OA) is a degenerative joint disease characterized by changes in the structure of the subchondral articular cartilage. Chondrocytes are responsible for the synthesis and integrity of the extracellular matrix of articular cartilage. Hyaluronic acid (HA) is believed to have a potential protective effect on joint cartilage through chondroprotective

AIM: This study compares the effect of HA administration on the expression of type-II collagen and type-X collagen in chondrocytes cartilage of end-stage OA. We hypothesized that there was an increase in the expression of COL2 and a decrease in COL10 in knee cartilage chondrocytes in end-grade OA patients with controls on HA.

MATERIALS AND METHODS: This study is experimental research (pre-and posttest control group design) with 20 samples divided into five groups, each consisting of four samples. Four different dosages of HA have been given to the treatment group: 0.1 mg/ml, 1 mg/ml, 2 mg/ml, and 3 mg/ml. Subsequently, collagen type II (COL2) and type X (COL10) were examined using the enzyme-linked immunosorbent assay method, and data were analyzed with SPSS 20.0

RESULTS: Our study revealed that COL2 expression was not significantly different between the control group and 0.1 mg/ml. Interestingly, with 1 mg/ml of HA, there was a markedly significant increase in the expression of COL2 (p < 0.05), and a further increase in dosage did not give an incremental effect. Conversely, the treatment of HA significantly suppressed the expression of COL10, but no enhanced suppression was found with increasing dose.

CONCLUSION: The administration of HA results in an increased number of COL2 and reduced number of COL10 and has the potential function of inhibiting the degeneration process in joint cartilage.

# Introduction

Osteoarthritis (OA) is the highest prevalence chronic joint disease and a major source of pain and disability in the United States and worldwide. With increasing life expectancy and obesity rates worldwide, the risk of OA has also increased and has become one of the major problems in the global health system [1]. OA is a chronic disease of the joints that causes pain due to inflammation. OA usually occurs in the knee, hip, and spine joints because they are the joints that support body weight [2]. The global prevalence of radiograph confirmed Kellgren-Lawrence grade 2-4 knee OA was estimated to be 3.8% of the population (4.8% women and 2.8% men). Whereas in Indonesia, the prevalence of knee OA is relatively high, reaching 15.5% in the male population and 12.7% in the female population with a distribution of 5% at <40 years old. 30% at 40-60 years old, and 65% at >61 years old [3]. OA is a complex disease caused by various factors involving changes in the subchondral articular bone and cartilage structure. This condition leads to signs and symptoms associated with impaired cartilage integrity and subchondral bone changes. Changes in cartilage structure include changes in chondrocytes as well as extracellular matrix. The conversion of chondrocytes to hypertrophic-like chondrocytes makes the chondrocytes have a round shape with a larger size, expresses type-X collagen from the COL10 gene, decreased collagen type II (COL2) expression from the COL2A1 gene, and expresses several other markers such as matrix metalloproteinase 13, RUNX2, and osteocalcin. Hypertrophic-like chondrocytes stimulate damage to surrounding cells, especially in conditions of OA [4]. OA management aims to control pain, optimize joint function, reduce physical limitations, improve quality of life, and inhibit disease progression. Nonoperative treatment is an option to reduce symptoms of OA, one of which is by administering an intraarticular injection of Hyaluronic Acid [5], [6].

Intraarticular injection of HA has been shown to have a protective effect on joint cartilage through several mechanisms, including mechanical effects, chondroprotective effects by reducing apoptosis and increasing chondrocyte proliferation, antiinflammatory effects, and increased proteoglycan and glycosaminoglycan synthesis [7].

Innormalcartilage, chondrocytes are responsible for the synthesis and integrity of the extracellular matrix of joint cartilage. Aggrecan (ACAN) and COL2 are major macromolecules and essential components in structuring the extracellular matrix. Therefore, damage in COL2 and loss of extracellular matrix components results in decreased matrix synthesis and joint cartilage tissue degradation regulation. Therefore, the balance between HA and COL2 is a critical parameter for determining the integrity of the extracellular matrix of joint cartilage [8]. In OA, articular chondrocytes differentiate into hypertrophic-like chondrocytes. The specific marker for hypertrophic-like chondrocytes is type-X collagen, expressed higher in patients with more severe cartilage degradation [4]. This study compares the effect of HA administration on the expression of type-II collagen and type-X collagen in chondrocytes cartilage of end-stage OA. We hypothesized that there was an increase in the expression of COL2 and a decrease in COL10 in knee cartilage chondrocytes in end-grade OA patients with controls on HA.

# **Methods**

#### Design study

The research design is in vitro true experimental research conducted in a laboratory to treat the research sample's tissue. This study design uses posttest only on the control and treatment groups.

#### Participants

The population of the research subjects is patients with knee OA who will undergo total knee replacement surgery at Saiful Anwar Hospital, Malang, Indonesia, in January–February 2021. The respondent is from the regular patient (nonpavilion) population.

#### Sample

We used 20 cartilage tissues from adult patients with knee OA who underwent total knee surgery at RSUD Dr. Saiful Anwar in January–February 2021 as samples in this research. The samples were divided into five groups consisting of one control group and four treatment groups with a total of 20 sample chondrocytes was taken from articular cartilage. This sample was obtained from repetition formula. The treatment groups received HA in various doses, namely 0.1 mg/mL, 1 mg/ml, 2 mg/ml, and 3 mg/ml, respectively. The cartilage tissue sample was then cultured and incubated for 3 days until the overall number of normal and hypertrophic-like chondrocyte cells increased. There were five experimental groups in this study, so the number of samples for each experimental group can be found using the formula below. These numbers were tested with a significance level of 0.05.

$$n^{3}\frac{15}{p}+1$$

# Description

n: repetition

p: experimental group

$$n \geq \frac{15}{5} + 1$$

 $n \geq 3+1 \rightarrow n \geq 4$ 

From this formula, if the number of treatments is 5, the number of repetitions needed for each treatment group is 4. Therefore, if we need five treatment groups, a minimum of chondrocyte cell groups from articular cartilage is 20 preparations required.

#### Data source/measurement

After the ethical application was approved, the research was carried out for 4 weeks, namely January–February 2021. Samples were taken when participants were on total knee replacement surgery. Surgery and sampling in this operation take 2–3 h from the completion of anesthesia. The selection itself takes 15–30 min during surgery in progress.

#### OA type

The samples in this study were end-stage OA with osteophytes to the central intraarticular areas and/or joint space narrowing up to >50% according to Ahlbäck stages 2–5 [9]. Another classification is the Kellgren-Lawrence classification stage 3–4, where there were progressive cartilage destruction, subchondral bone exposure, and the presence of a hard ivory-like area called eburnation on the weight-bearing area (medial/ lateral condyle) [10], [11].

#### HA

HA used in this study was the Umarone<sup>®</sup> which was given to chondrocyte cultures in culture media with different doses for each treatment group [12].

# Type X and type II collagen level measurement

Type X collagen is produced by hypertrophiclike chondrocytes, whereas type II collagen is produced by chondrocyte cells. Therefore, after three days of culture, there was an increase in the overall number of normal and *hypertrophic-like chondrocytes*. Then, the cultures were taken for the examination using enzyme-linked immunosorbent assay (ELISA) with Human COL2 antibodies and Human COL10 ELISA-kit (Bioassay Technology Laboratory<sup>®</sup>). These measurements were carried out after the administration of HA.

### The inclusion and exclusion criteria

The inclusion criteria were the cartilage obtained from OA patients on total knee replacement procedure, normal chondrocytes (cobblestone), and hypertrophic-like chondrocytes were found in the culture field, cartilage cultures were confluent after 3 days of cell incubation (overall chondrocyte count increased per field), cartilage culture plates are not contaminated (bacteria), and if it is not included in the inclusion criteria, then it is grouped into the exclusion criteria.

#### Variables

Independent Variables: HA applied to culture cell media. Dependent Variables: Expression of COL10 and COL2 in chondrocytes.

To prevent bias in this study, we have selected samples based on inclusion criteria and maintained the quality of the study by controlling the control variables consisting of sampling in the end-stage of OA, how to collect and store articular cartilage, and process chondrocyte cell culture according to the standard. The independent variable in this research was administering HA to cell culture media. The independent variable in this research was the expression of COL10 and COL2 in chondrocytes. The Ethical Committee of Medical Research Faculty of Medicine Universitas Brawijaya has approved all protocols, and all subsequent experiments were carried out according to the relevant guidelines and regulations.

#### Statistical methods

All the samples of this study were analyzed with statistical software, and no one of the samples is missing to be analyzed because all of them include in the inclusion criteria. Data obtained were analyzed using the Shapiro–Wilk normality test to check the data distribution. If data are normally distributed, then the one-way analysis of variance (ANOVA) and Tukey parametric tests are performed, whereas if data are not normally distributed, the Kruskal–Wallis and Mann–Whitney nonparametric tests are performed. One-way ANOVA has an error rate of 5% or a 95 % level of confidence, and the Kruskal–Wallis test was used to compare the difference of means among all groups. The *post hoc* test using Mann–Whitney and Tukey test was performed to assess all possible pairwise comparisons between groups. The p < 0.05 was considered statistically significant. Data analysis was performed using SPSS version 25.0 software.

## Results

#### Descriptive data

Descriptive analysis is intended to determine the general description of the research variables. In addition, this descriptive analysis is expected to provide an overview of the state of patient data. To find out the description for each variable can be seen in this table (Table 1).

Table 1: Descriptive results

Collagen	Dose	n	Mean	Std. Deviation
Collagen Type II	0	5	78.378	2.979
	0.1 mg/ml	5	74.044	8.086
	1 mg/ml	5	122.067	13.872
	2 mg/ml	5	105.845	7.440
	3 mg/ml	5	113.422	8.573
Collagen Type X	0	5	24.096	0.537
	0.1 mg/ml	5	4.793	0.256
	1 mg/ml	5	6.619	0.362
	2 mg/ml	5	6.182	0.451
	3 mg/ml	5	5.954	0.144

Based on the description above, we have not shown the results of the study. Therefore, a hypothesis test was conducted using a one-way ANOVA to find the research results with an error rate of 5% or a 95% level of confidence. However, before using parametric statistics, the first test of normality and data homogeneity is required. The normality test using Shapiro–Wilk showed that the significance value (p) of COL2 is p = 0.185. In contrast, COL10 is p < 0.0001, so it can be concluded that COL2 distribution is normal while COL10 is not distributed normally.

Furthermore, for the homogeneity test (Levene Test), COL2 and COL10 have significance p = 0.0067 and p = 0.435 consecutively, so both results have homogeneous data (Table 2). Therefore, from the data, researchers will use the ANOVA test to be used on COL2 and nonparametric statistical testing on COL10. Furthermore, a one-way ANOVA test determines differences between treatment groups and tests whether there is a significant difference between one treatment and another. If p < 0.05 for COL2 parameter, hypothesis 0 (H<sub>0</sub>) is rejected (Table 3). As a result, there were

Test	Collagen type II	Collagen type >
Normality test		
N	25	25
Р	0.185	0.000
Homogeneity test		
Levene Statistic	2.608	2.225
df1	4	4
df2	20	20
Р	0.067	0.435

Table 3: One-way ANOVA, Kruskal–Wallis, and Spearman's Correlation Test Results

Test result	Parameter	E	<b>n</b>	r	Information
Test Tesuit	Farameter	Г	р	1	mormation
One-way ANOVA test	Collagen Type II	28.992	0.000	-	Significant
Kruskal–Wallis test	Collagen Type X	-	0.000	-	Significant
Spearman's correlation	Dose – Type II Collagen	-	0.000	0.665	Significant
test	Dose – Type X Collagen	-	0.101	-0.335	Nonsignificant
ANO//A: Analysis of variance					

meaningful differences between the treatment groups and obtained a significance p for COL2, p < 0.0001. Hence, it can be concluded that there were significant differences in influence between doses with a 95% confidence level.

Then, we conducted Tukey tests for COL2 to compare each treatment group. It was found that doses of 0 mg/ml and 0.1 mg/ml did not have significant differences because it has a p = 0.936, while doses of 0 mg/ml and 1 mg/ml had considerable significance with doses of 1 mg/ml, 2 mg/ml, and 3 mg/ml significance which has a p < 0.0001 (Table 4).

#### Table 4: Tukey test results for collagen type II

Dosage differences	Average difference	р	Information
0			
0.1 mg/ml	4.333	0.936	Nonsignificant
1 mg/ml	-43.689	0.000	Significant
2 mg/ml	-27.467	0.001	Significant
3 mg/ml	-35.044	0.000	Significant
0.1 mg/ml			
1 mg/ml	-48.022	0.000	Significant
2 mg/ml	-31.800	0.000	Significant
3 mg/ml	-39.378	0.000	Significant
1 mg/ml			
2 mg/ml	16.222	0.062	Nonsignificant
3 mg/ml	8.645	0.552	Nonsignificant
2 mg/ml			-
3 mg/ml	-7.577	0.666	Nonsignificant

Then, we are conducting a Kruskal–Wallis test for COL10 data to determine whether there is a significant difference between treatments and a considerable difference between one treatment and another. Based on the analysis results, a p < 0.0001 means a significant difference between the dose at the 95% confidence level (Table 3).

The comparison between each group after the Kruskal–Wallis test was carried out, followed by using the Mann–Whitney test. The results of the Mann– Whitney test that the dose has a difference between groups is shown if it has a p < 0.05 (Table 5).

Table 5:	Mann-Whitney	y test results
----------	--------------	----------------

Difference dosage	Average difference	р	Information
0			
0.1 mg/ml	19.303	0.009	Significant
1 mg/ml	17.477	0.009	Significant
2 mg/ml	-0.206	0.009	Significant
3 mg/ml	18.142	0.009	Significant
0.1 mg/ml			-
1 mg/ml	-1.826	0.009	Significant
2 mg/ml	-19.509	0.009	Significant
3 mg/ml	-1.161	0.009	Significant
1 mg/ml			
2 mg/ml	-17.682	0.047	Significant
3 mg/ml	0.665	0.028	Significant
2 mg/ml			-
3 mg/ml	18.347	0.009	Significant

The results of the Mann–Whitney test, COL10 comparison between other doses have a

significant difference in collagen levels. Furthermore, the researchers conducted a correlation test between the dose with COL2 and COL10, this purpose of determining whether there is a relationship or not that can be seen from the significance or (p) value and how strong the relationship can be seen from the correlation coefficient value or (r).

The relationship between dosage - COL2 is known that the correlation value is 0.665 with a p of 0.000, the correlation value of 0.665 indicates that the dose with COL2 has a strong relationship, and with a positive relationship suggests that the higher the dose will give an increase in level COL2. Meanwhile, with p = 0.000 < 0.05 ( $\alpha = 5\%$ ), it can be concluded that there is a significant relationship between the dose HA and COL2. However, the relationship between dosage -COL10 is known that the correlation value is -0.335 with a p of 0.101, the correlation value of 0.335 indicates that the dose with COL10 has a weak relationship and with a negative relationship suggests that the higher the dose will decrease COL10 level. Meanwhile, with p = 0.101 > 0.05 ( $\alpha = 5\%$ ), it can be concluded that there is a nonsignificant relationship between the dose HA and COL10 (Table 3).

## Discussion

In OA conditions, COL2 will undergo two main mechanisms: anabolic and catabolic, with some of the chondrocytes in cartilage will undergo terminal differentiation into hypertrophic-like chondrocytes. Hypertrophic-like chondrocytes will express extracellular matrix in the form of COL10, which is a specific marker. Meanwhile, normal chondrocytes that do not undergo differentiation will still express COL2 even with a decreased concentration compared to normal cartilage conditions. This condition is caused by the unbalanced anabolic and catabolic responses of COL2, especially in states of severe cartilage damage [13]. Meanwhile, a high level of COL2 as an extracellular matrix, especially in cartilage, helps improve structural integrity in cartilage and helps the body respond to joint cartilage repair.

In this study, there was a decrease in COL2 level in the control group, and after receiving a 0.1 mg/ml dose of HA in the treatment group, there was still no increase in the expression of COL2. However, with a dose of 1 mg/ml, a significant increase in COL2 was seen. The different finding is shown with the higher dose of HA, with 2 mg/mL and 3 ml/mL, there was no further increase of COL2. This result is in parallel with the research of Alleman *et al.*, in an in vitro experiment where an HA scaffold was inserted into the chondrocyte culture environment; the results of measurements using polymerase chain reaction showed that administration of HA scaffold with a dose of 2% could increase the mRNA

Title and abstract     1     (a) Indicate the subcy's design with a commonly used term in the title or the abstract     2     This research is <i>n</i> witre experimental research (per-and postetic control group design)       Introduction Background/instantes     2     Explain the abstract an informative and balanced summary of what was done and what was found     3-4     (per-and postetic control group design) (n the point of the objective and the result       Introduction Background/instantes     2     Explain the scientific background and rationale for the investigation being reported States specific objectives, including any prespecified hypotheses     3-4     We hypothesized       State-specific objectives, including any prespecified hypotheses     3-4     We hypothesized     3-4       Participants     6     (a) Give the eligibility criteria and the sources and methods of selection of participants     5-6     The inclusion criteria were       Data sources     0     For each variable of interest, give sources of data and delais of methods of assessment (measurement). Describe any site was strived of analyses. If applicable, to the analyses of the objective and the study     20 sample       Bias     9     Describe any methods used to examine subgroups and interactors mode than one groups     7     Statistical analysis       Study size of the analyses     11     Explain hym issing data asses to poterinity apply is were	Item Details	Item No	Recommendation	Page No	Relevant text from manuscript
and what was found with was found w	Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2	This research is in vitro experimental research
and what was foundand what was foundBackground/rationale2Staplian the scientific background and rationale for the investigation being reported Methods3-4Ve hypothesizedSetting3Status design5Sample collection and data acquisitionSetting5Present key elements of study design early in the article Describe the setting, locations, and relevant datas, including periods of rearcument, Numbels5Sample collection and data acquisitionParticipants6(a) Give the setting, locations, and relevant datas, including periods of selection of participants reservement, Describe presented, locations, and relevant datas, including periods of selection of participants5Sample collectionParticipants7Chearty data call action5The inclusion criteria were5Participants9Describe any efforts to address potential sources of bias describe withing groupings were chosen and wity6To prevent bias in this studyStudy gize10Explain how quantifiev variables were handled in the analyses, If applicable, describe any efforts to address of the analyses7Statistical analysisStatistical methods, including these used to control for control for adminus study7Statistical analysisParticipants13(a) Report numbers of individing these used to control for control moding (b) Describe any efforts in addressed (c) Consider the used of affort dagsand (d) If applicable, describe analytical methods individing these used to control for controlunding (b) Describe any embods used to examine subgroups and interactions (d) Describe any embods used to exami					(pre-and posttest control group design)
Background/ational Objectives     Sexplain the scientific background and rationale for the investigation being reported Methods     3-4- 4     We hypothesized       Methods     Present key elements of study design early in the article Setting     5-8     Sample collection and data acquisition       Participants     6     (a) Cive the esting, locations, and relevant datas, including periods of recruitment, Setting     5-8     The inclusion criteria were       Participants     6     (a) Cive the esting light or theria and the sources and methods of selection of participants measurement     5-8     The inclusion criteria were       Data sources/ measurement     8*     Explain the esting light or theria and the sources of balas measurement bias in the study     5-8     To prevent bias in this study       Bias     9     Describe any efforts caddress potential sources of balas measurement bias in the study     5-8     Sample collection and yais and the source of balas measurement bias in the study       Study design     10     Explain how quantifies variables were handed in the analyses. If applicable, describe any efforts and adress balang and the source of the source				2	In the point of the objective and the result
Objectives     3     State-specific objectives, including any prespecified hypothesis     4     We hypothesized       Study design     4     Present key elements of study design early in the article     5     Sample collection and data acquisition       Participants     5     Describe the setting, locations, and relevant dates, including periods of selection of participants     5     The inclusion criteria were       Participants     6     (2) low the eligibility orther and the sources and methods of selection of participants     5     The inclusion criteria were       Variables     7     Clearly define all cultomes, exposures, predictors, potential confoundens, and define all cultomes, exposures, predictors, potential confoundens, and define all cultomes, exposures of blas     6     To prevent blas in this study       Blas     9     Describe any efforts to address potential sources of blas     6     To prevent blas in this study       Study size     10     Explain how unsitely data were addressed     7     Statistical matysis       10     Describe any emotion used to seame subgroups and interactions     7     Statistical analysis       11     Explain how unsitely data were addressed     7     Statistical analysis       12     (2) Describe any emotion use unstat					
Study design   4   Present key elements of study design early in the article   5   Sample collection and data acquisition     Setting   5   Describe the setting locations, and relevant date, including periods of reruntment, exposure, follow-up, and data collection   5-6   Sample collection and data acquisition     Variables   7   Clearly define all outcomes, exposures, predictors, potential contounders, and effect   5   Sample collection     measurement   Samsessment (messurement). Describe comparability of assessment methods if there is more than one group   7   Sample collection     Bias   9   Describe any setting to setting setting in the study set were handle in the analyses. If applicable, describe which groupings were chosen and why   7   Statistical analysis (at analysis (	Objectives				We hypothesized
Participants 6 (G) vero the eligibility criteria and the sources and methods of selection of participants 5 The inclusion criteria were Variables 7 (G) vero the eligibility criteria and the sources and methods of selection of participants 5 Sample collection modifiers. Give damostic criteria, fapplicable, diagnostic criteria, fapplicable, diagnostic criteria, applicable, diagnostic criteria, applicable, diagnostic criteria were substrates and the sources of blas 6 C To prevent blas in this study Blas 9 Describe any efforts to address potential sources of blas 6 C To prevent blas in this study Study zize 10 Explain how the study size was arrived at 5 20 Sample Quanitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, discribe which groupings were chosen and why Statistical methods 12 (D) Describe any methods taking account of sampling strategy (D) Describe any methods used to examine subgroups and interactions (D) Describe any methods used to examine subgroups and interactions (D) Describe any methods taking account of sampling strategy (D) Describe any methods taking account of sampling strategy (D) Describe any sentifyily analyzes 7 Statistical analysis 7 Statistical analysis 8 Mon missing data were addressed (D) Figure reasons for nonparticipation at each stage (D) Consider the use of affw diagram 1 Participants 12 (a) Give characteristics of study participants (eg demographic, clinical, and social) and 1 mormation on exposures and potential confounders (D) Indicate the number of participants when confinuous variables when confinuous variables were adjusted for and why they were included 2 Ne sources of outcome ever sol runs and potential confounders were adjusted for and why they were included 3 Ne samples are excluded 3 Ne samples are excluded 3 Ne samples are excluded 3 Ne sampl		4	Present key elements of study design early in the article	5	Sample collection and data acquisition
Participants   6   (a) Give the eligibility circleria and the sources and methods of selection of participants   5   The inclusion criteria were     Variables   7   Clearly define al outcomes, exposores, production confounders, and effect   5   Sample collection     Data sources?   8*   For each variable of interest, give sources of data and details of methods of   7   Statistical methods   7     Bias   9   Describe any efforts to address potential sources of bias   6   To prevent bias in this study     Study size   10   Explain how the tothy size was a strifted at   6   To prevent bias in this study     Study size   10   Explain how the integration became and with a sources of bias   6   To prevent bias in this study     Statistical methods   12   (a) Describe any strifted at the examine subgroups and interactions   7   Statistical analysis     Statistical methods   (b) Describe any methods used to examine subgroups and interactions   7   Statistical analysis     Participants   13*   (a) Report numbers of individuals at each stage of the study — e.g. numbers   7   Statistical analysis     Participants   13*   (a) Give characteristics of study participants (eg demographic. cinical, and social) and information on exp	Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,	5-6	
Data sources measurementPor each variable interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is immet han one group7Bias Study size9Describe any efforts to address potential sources of bias texplain how the study size variables6To prevent bias in this study 20 SampleStudy size10Explain how the study size variables describe which groupings were chosen and why (a) Describe any methods used to examine at disprops (b) Explain how mesing data were addressed (c) Explain how mesing data were addressed (c) Explain how mesing data were addressed (c) Explain how sensitivity and malyses7Statistical analysis No missing dataResults12*(a) Report numbers of individuals at each stage (c) Describe any sensitivity analyses7Statistical analysis No missing dataParticipants13*(a) Report numbers of individuals at each stage (c) Consider the use of a flow dargam (c) Consider the use of a flow dargam7-9ResultOutcome data Main results16*(a) Give characteristics of study participanis (e) demographic, clinical, and social and data for each variable of interest (c) Consider the number of participanis (e) demographic, clinical, and social) and information on exposures and potential confounders (c) Consider the number of participation at each stage (c) Consider the use of a flow dargam7-9ResultOutcome data Main results15*(a) Give characteristics of study participations (e) demographic, clinical, and social) and information on exposures and potential confounders (c) Report classes of subgroups and interactions and<	Participants	6	(a) Give the eligibility criteria and the sources and methods of selection of participants	5	The inclusion criteria were
measurement   assessment (measurement). Describe comparability of assessment methods if there is more than one group     Bias   9   Describe any efforts to address potential sources of bias   6   To prevent bias in this study     Study size   10   Explain how the study size was arrived at   20 Sample     Cuantifative variables   11   Explain how untefficie variables were handled in the analyses. If applicable, describe which groupings were chosen and why   7   Statistical analysis     Statistical methods   12   (a) Describe any methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions   7   Statistical analysis     C) Explain how missing data were addressed   7   Statistical analysis   7   Statistical analysis     Results   Participants   13*   (a) Report numbers of individuals at each stage of the study – e.g., numbers   7   Statistical analysis     Describe nay methods   (b) Give reasons for nonparticipation at each stage   7   Statistical analysis     Descriptive data   14*   (a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders   7-9   Result     Descriptive data   15*   Report category boundaries when continnous variables	Variables	7		5	Sample collection
Bias9Describe any efforts 10 address potential sources of bias6To prevent bias in this studyStudy size10Explain how the study size was arrived at520 SampleQuantitative variables11Explain how quantitative variables were chosen and why7Statistical analysisStatistical methods12(a) Describe any methods used to examine subgroups and interactions (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe any addressed (e) Describe any sensitivity analyses7Statistical analysis No missing dataResults13*(a) Report numbers of individuals at each stage of the study — e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed (b) Consider the use of a flow diagram information on exposures and potential confounders (b) Consider the use of a flow diagram information on exposures and potential confounders (c) Consider the use of a flow diagram information on exposures and potential confounders (c) Consider the use of a flow diagram information on exposures and potential confounders (c) Consider the use of a flow oreally set of reactive risk for a maaningful time period7-9ResultOutcome data15'(a) Glow unadjusted estimates and, if applicable, confounders were adjusted for and why they were included (c) If relevant, consider translating estimates of relative risk into absolute risk for a maaningful time period10-12TableOutcome data15'Sumarize key results with reference to study objectives informations of the study, taking ind ascoun	Data sources/	8*	For each variable of interest, give sources of data and details of methods of	7	
Bias     9     Describe any efforts to address potential sources of bias     6     To prevent bias in this study       Study size     10     Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why     20 Sample       Statistical methods     12     (a) Describe any statistical methods, including those used to control for confounding (b) Describe any statistical analysis     7     Statistical analysis       (b) Describe any statistical methods isking account of sampling strategy     5     Sample       Participants     13*     (a) Report numbers of individuals at each stage of the study — e.g., numbers or potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-u.p. and analyzed (b) Give reasons for nonparticipanto at each stage     7–9     Result       Descriptive data     14*     (a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders     8–1     No samples are excluded       Outcome data     15*     Report numbers of participants with missing data for each variable of interest (b) Indicate the number of participants with missing data for each variable of interest (c) Origider the use of a flow diagram     8–9     Result       Outcome data     16*     Report numbers of outcome events or summary measures and pattentical confounders du	measurement				
Quantitative variables   11   Excitation was an excitation was and excitation was an excitation was an excitation exc	Bias	9		6	To prevent bias in this study
describe which groupings were chosen and why   7   Statistical methods,     Statistical methods   12   (a) Describe any methods used to control for confounding (b) Describe any methods used to control for confounding (c) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed   7   Statistical analysis No missing data     Results   (a) Describe any sensitivity analyses   5   Sample     Participants   13*   (a) Report numbers of individuals at each stage of the study — e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed (b) Give reasons for nonparticipation at each stage   7-9   Result     Descriptive data   14*   (a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders (c) Consider the use of a flow diagram   No samples are excluded     Outcome data   15*   Report numbers of uctome events or summary measures   17-19   Table     Main results   16   (a) Give unalysted estimates and, if applicable, confounder-adjusted estimates   17-19   Table     Other analyses   17   Results   8-9   Results     Discussion   16   (b) Report category boundaries when continuous variables were categorized (c) (F) relevant, consider translating estimates of relative	Study size	10	Explain how the study size was arrived at	5	20 Sample
Statistical methods   12   (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe any Autistical methods taking account of sampling strategy (e) Describe any sensitivity analyses   7   Statistical analysis No missing data     Results   7   Statistical methods (d) If applicable, describe any Autistivity analyses   7   Statistical methods (d) If applicable, describe any Autistivity analyses     Participants   13*   (a) Report numbers of individuals at each stage of the study — e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed (c) Consider the use of a flow diagram   7-9   Result     Descriptive data   14*   (a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders (b) Indice the numbers of outcome events or summary measures   No samples are excluded     Outcome data   15*   Report numbers of outcome events or summary measures and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included   17-19   Table     Outcome data   16   (b) Report outparies when continuous variables were categorized (c) If relevant, consider transluting estimates of relative risk into absolute risk for a meaningful time period   8-9   Results	Quantitative variables	11			
(b) Describe any methods used to examine subgroups and interactions7Statistical analysis No missing data(c) Explain how missing data were addressed5Sample(d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses5SampleParticipants13*(a) Report numbers of individuals at each stage of the study — e.g., numbers optimulay eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed (b) Give reasons for nonparticipation at each stage7-9ResultDescriptive data14*(a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders (c) Consider the use of a flow diagramNo samples are excludedOutcome data15*Report numbers of outcome events or summary measures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) Indicate the number of participants or summary measures adjusted for and why they were included (c) If relevant, consider translating estimates of relative risk into absolute risk for a sensitivity analyses17-19TableOther analyses17Report other analyses of relative risk into absolute risk for a sensitivity analyses10-12DiscussionDiscussion18Summarize key results with reference to study objectives imprecision. Discuss both direction on for switcoscidering objectives, limitations of analyses active audious deriven for switcoscidering objectives, limitations of imprecision. Discuss both direction and magnitude of any potential bias or imprecision. Discuss					
(c)   Explain how missing data were addressed   No missing data     (d)   If applicable, describe analysitical methods taking account of sampling strategy   5   Sample     Participants   13*   (a) Report numbers of individuals at each stage of the study — e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed   7-9   Result     Descriptive data   14*   (a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders   No samples are excluded     Outcome data   14*   (a) Give unadjusted estimates and, if applicable, confounder substance   17-19   Table     Main results   16   (a) Give unadjusted estimates and, if applicable, confounder substance   17-19   Table     Main results   16   (a) Give unadjusted estimates and, if applicable, confounder substance   8-9   Results     Olter analyses   17   Report characteristing estimates of relative risk into absolute risk for a meaningful time period   8-9   Results     Other analyses   18   Summarize key results with reference to study objectives   10-12   Discussion     Interpretation   20   Give catucus overall interpretion of results consolating objectives, limitations of the stud	Statistical methods	12			
(a) (1) applicable, describe analytical methods taking account of sampling strategy (b) Describe any sensitivity analyses5Sample Statistical analysisResults7Statistical analysisParticipants13*(a) Report numbers of individuals at each stage of the study — e.g., numbers potentially eligibile, examined for eligibility, comfinded eligible, included in the study, completing follow-up, and analyzed (b) Give reasons for nonparticipation at each stage (c) Consider the use of a flow diagram7-9ResultDescriptive data14*(a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interestNo samples are excludedOutcome data15*Report numbers of outcome events or summary measures (c) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report other analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses10-12DiscussionDiscussionKeresults18Summarize key results with reference to study objectives unalyses done — e.g., analyses of potential bias or imprecision. Discuss both direction and magnitude of any potential bias ensitivity analysesDiscussionDiscussion1010-12DiscussionCuttor18Summarize key results with reference to study objectives unalyses done — e.g., analyses of potential bias or imprecision. Discuss both direction and magnitude of any potential bias imprecisio				7	
(e) Describe any sensitivity analyses   7   Statistical analysis     Results   Participants   13*   (a) Report numbers of individuals at each stage of the study — e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed   7–9   Result     Descriptive data   14*   (a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders   8   No samples are excluded     Outcome data   15*   Report numbers of outcome events or summary measures   17–19   Table     Main results   16   (d) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and if applicable, confounders were adjusted for and why they were included   8–9   Results     Other analyses   17   Report numbers of summary measures   17–19   Table     Other analyses   17   Report during estimates of relative risk into absolute risk for a meaningful time period   8–9   Results     Discussion   18   Summarize key results with reference to study objectives   10–12   Discussion     Key result   18   Summarize key results with reference to study objectives, limitations, multiplicity of analyses, results for a imprecision. Discuss both direction and magnitude of any potential bias or imprecision. Discuss b				-	
Results   13*   (a) Report numbers of individuals at each stage of the study — e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed   7-9   Result     Descriptive data   14*   (a) Give crassons for nonparticipation at each stage   No samples are excluded     Descriptive data   14*   (a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders   8     Outcome data   15*   Report numbers of outcome events or summary measures   17-19   Table     Main results   16   (a) Give unadjusted estimates and, if applicable, confounders were adjusted for and why they were included   8-9   Results     Outcome data   15*   Report tarmslating estimates of relative risk into absolute risk for a meaningful time period   8-9   Results     Other analyses   17   Report tother analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses   8-9   Results     Discussion   Key results with reference to study objectives   10-12   Discussion     Key results   18   Summarize key results with reference to study objectives, limitations, multiplicity of analyses, nesults form and potential bias or imprecision. Discuss both direction and magnitude of any potential bias or multiplicity of analyse					
Participants13*(a) Report numbers of individuals at each stage of the study — e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed (b) Give reasons for nonparticipation at each stage (c) Consider the use of a flow diagram7-9ResultDescriptive data14*(a) Give characteristics of study participants (eg demographic, clinical, and social) and a) Give characteristics of study participants (eg demographic, clinical, and social) and (b) Indicate the number of participants with missing data for each variable of interest (b) Indicate the number of participants with missing data for each variable of interest (b) Indicate the number of participants with missing data for each variable of interest (c) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period8-9ResultsOther analyses17Report other analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses10-12DiscussionKey results18Summarize key results with reference to study objectives imprecision. Discuss both direction and magnitude of any potential bias or imprecision. Discuss both direction and magnitude of any potential bias minteristics of study societion of measults10-11InterventionInterpretation20Give a cautious overall interpretation of feestlifts, initiations, multiplicity of analyses, results from similar stud	Results		(e) Describe any sensitivity analyses	'	Statistical analysis
(b) Give reasons for nonparticipation at each stage   No samples are excluded     (c) Consider the use of a flow diagram   (a) Give characteristics of study participants (eg demographic, clinical, and social) and information on exposures and potential confounders   8     Outcome data   15*   Report numbers of outcome events or summary measures   17-19   Table     Main results   16   (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were includedd   8-9   Results     Other analyses   17   Report number of and with ye were includedd   8   8-9     Other analyses   17   Report other analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses   8-9   Results     Discussion   Key results   18   Summarize key results with reference to study objectives   10-12   Discussion     Interpretation   19   Discuss bin direction and magnitude of any potential bias or imprecision. Discuss both direction and magnitude of any potential bias or imprecision. Discuss both direction and magnitude of any optential bias   10-12   Discussion     Iterpretation   20   Give a cautious overal interpretation of easults considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant e		13*	potentially eligible, examined for eligibility, confirmed eligible, included in the study,	7-9	Result
Descriptive data   14*   (a) Give characteristics of study participants (eg demographic, clinical, and social) and a information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest   1   Table     Outcome data   15*   Report numbers of outcome events or summary measures   17–19   Table     Main results   16   (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included   8–9   Results     0/b   Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   8–9   Results     0/bre analyses   17   Report other analyses of one — e.g., analyses of subgroups and interactions and sensitivity analyses   10–12   Discussion     Eimitations   19   Discuss limitations of the study, taking into account sources of potential bias   10–12   Discussion     Iterpretation   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   10–11     Other information   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results					No samples are excluded
Outcome data   15*   Report numbers of outcome events or summary measures   17-19   Table     Main results   16   (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included   8-9   Results     0 (b) Report category boundaries when continuous variables were categorized   (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   8-9   Results     Other analyses   17   Report other analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses   10-12   Discussion     Key results   18   Summarize key results with reference to study objectives   11   11     Interpretation   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   10-11     Other relizability   21   Discuss the generalisability (external validity) of the study results   11			(c) Consider the use of a flow diagram		
(b) Indicate the number of participants with missing data for each variable of interest17-19TableOutcome data15*Report numbers of outcome events or summary measures17-19TableMain results16(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg. 95% confidence interval). Make clear which confounders were adjusted for and why they were included8-9Results(b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period17Report other analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses10-12DiscussionDiscussion18Summarize key results with reference to study objectives imprecision. Discuss both direction and magnitude of any potential bias multiplicity of analyses, results from similar studies, and other relevant evidence10-11IoenticInterpretation20Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence10-11IoenticOther information21Discuss the generalisability (external validity) of the study results11Ioentic	Descriptive data	14*		8	
Outcome data   15*   Report numbers of outcome events or summary measures   17-19   Table     Main results   16   (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included   8-9   Results     (b) Report category boundaries when continuous variables were categorized   (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   8-9   Results     Other analyses   17   Report other analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses   10-12   Discussion     Every results   18   Summarize key results with reference to study objectives imprecision. Discuss both direction and magnitude of any potential bias or imprecision. Discuss both direction and magnitude of any potential bias   10-12   Discussion     Interpretation   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   10-11     Generalizability   21   Discuss the generalisability (external validity) of the study results   11					
Main results   16   (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg. 95% confidence interval). Make clear which confounders were adjusted for and why they were included   8-9   Results     (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   8-9   Results     Other analyses   17   Report other analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses   10-12   Discussion     Eiscussion   18   Summarize key results with reference to study objectives imprecision. Discuss both direction and magnitude of any potential bias imprecision. Discuss both direction and magnitude of any potential bias   10-12   Discussion     Interpretation   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   10-11     Other information   21   Discuss the generalisability (external validity) of the study results   11					
their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included   (b) Report category boundaries when continuous variables were categorized   (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period     Other analyses   17   Report other analyses done – e.g., analyses of subgroups and interactions and sensitivity analyses     Discussion   10-12   Discussion     Key results   18   Summarize key results with reference to study objectives of potential bias or imprecision. Discuss both direction and magnitude of any potential bias   10-12   Discussion     Interpretation   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   10-11     Generalizability   21   Discuss the generalisability (external validity) of the study results   11					
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period     Other analyses   17   Report other analyses of subgroups and interactions and sensitivity analyses     Discussion   8   Summarize key results with reference to study objectives   10–12   Discussion     Limitations   19   Discuss both direction and magnitude of any potential bias   11   11     Interpretation   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   10–11     Other information   21   Discuss the generalisability (external validity) of the study results   11	Main results	16	their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-9	Results
Other analyses   17   Report other analyses done — e.g., analyses of subgroups and interactions and sensitivity analyses     Discussion   Exercise   10–12   Discussion     Key results   18   Summarize key results with reference to study objectives   10–12   Discussion     Limitations   19   Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias   11   10–11     Interpretation   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   10–11     Generalizability   21   Discuss the generalisability (external validity) of the study results   11			(c) If relevant, consider translating estimates of relative risk into absolute risk for a		
Discussion 10-12 Discussion   Key results 18 Summarize key results with reference to study objectives 10-12 Discussion   Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 11 10-11   Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 10-11   Generalizability Other information 21 Discuss the generalisability (external validity) of the study results 11	Other analyses	17			
Discussion 10-12 Discussion   Key results 18 Summarize key results with reference to study objectives 10-12 Discussion   Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 11 11   Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 10-11   Generalizability 21 Discuss the generalisability (external validity) of the study results 11	Other analyses	17			
Key results 18 Summarize key results with reference to study objectives 10-12 Discussion   Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 11 11   Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 10-11   Generalizability Other information 21 Discuss the generalisability (external validity) of the study results 11	Discussion		Scholuvity analyses		
Limitations   19   Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias   11     Interpretation   20   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   10-11     Generalizability Other information   21   Discuss the generalisability (external validity) of the study results   11		18	Summarize key results with reference to study objectives	10-12	Discussion
imprecision. Discuss both direction and magnitude of any potential bias Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Generalizability 21 Discuss the generalisability (external validity) of the study results 11 Other information					
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 10-11   Generalizability Other information 21 Discuss the generalisability (external validity) of the study results 11					
Generalizability   21   Discuss the generalisability (external validity) of the study results   11     Other information   11	Interpretation	20		10-11	
Generalizability 21 Discuss the generalisability (external validity) of the study results 11   Other information 11					
		21		11	
applicable, for the original study on which the present article is based	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14	Role of the funding source

#### Strobe Statement - Checklist of items that should be included in reports of cross-sectional studies

"Give information separately for exposed and unexposed groups. An explanation and elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.pidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

expression of COL2 up to four times. However, the same study also showed that giving HA levels that are too large, at a dose of 10%, would inhibit the expression of COL2 [14]. Therefore, data concluded that the dose of 1 mg/mL is the optimal dose that could increase the expression of COL2. In addition, it is necessary to pay attention to the optimal and not excessive dose of HA so that it does not inhibit the expression of COL2.

HA also inhibits the effect of IL-1 $\beta$  and NO on the activation of the RUNX2 gene, thereby inhibiting the differentiation process of terminal chondrocytes (hypertrophic-like chondrocytes) [15]. Furthermore, this inhibition will make the number of hypertrophic-like chondrocyte cells do not increase but decrease due to the tendency of these cells to experience apoptosis.

A specific marker for hypertrophic-like chondrocytes is COL10. Normal chondrocytes cannot extract this specific substance in human joint cartilage. Therefore, COL10 levels would be detected at protein and mRNA levels in human cartilage with OA. COL10 levels will be found higher in OA, which suffered from more severe tissue degradation [16]. There is an association between COL10 levels and the severity of OA. The higher the level of COL10 indicates, the more profound the gap in the cartilage and the more exposed the subchondral bone [17].

Oxidative stress and inflammatory reactions are also occurring in the OA culture sample, therefore increasing terminal differentiation and hypertrophic-like activity of chondrocytes as evidenced by increased levels of COL10. The increased hypertrophic-like activity of chondrocytes will increase levels of MMPs, especially MMP-13, an enzyme capable of breaking down extracellular matrices and aggravating cartilage damage in individuals with OA [17].

In this study, a decrease of COL10 expression was significant among all doses of HA. In addition, the negative relationship between the dose and COL10 in Spearman's correlation test showed that administering a more significant amount of HA would reducing COL10. In other words, every additional milligram dose of HA will suppress the expression of COL10. This theory follows the theory that HA plays a significant role in suppressing COL10 and provides a protective effect against OA [18], [19].

For future research, the authors suggest that in vivo studies with more variables such asACAN, SOX9, and other substances can be carried out to observe HA administration's biological responses better.

# Conclusion

The administration of HA can increase COL2 and decrease COL10, so it has the potential function of inhibiting the degeneration process in joint cartilage. The optimal dose of HA found in this study was 1 mg/mL.

# The Point in this Study Adds

- 1. The optimal effective dose of HA for the chondroprotective effect based on COL2 and COLX levels is 1mg/mL.
- 2. The higher dose of HA did not increase COL2 further than 1mg/mL.
- 3. Administering a higher dose of HA significantly suppresses the COL10 even more.

# References

 Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: Estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-30. https://doi.org/10.1136/ annrheumdis-2013-204763

PMid:24553908

- Wallace IJ, Worthington S, Felson DT, Jurmain RD, Wren KT, Maijanen H, *et al.* Knee osteoarthritis has doubled in prevalence since the mid-20<sup>th</sup> century. Proc Natl Acad Sci U S A. 2017;114(35):9332-6. https://doi.org/10.1073/pnas.1703856114 PMid:28808025
- Arden N, Nevitt MC. Osteoarthritis: Epidemiology. Best Pract Res. 2006;20(1):3-25. https://doi.org/10.1016/j.berh.2005.09.007 PMid:16483904
- Van der Kraan PM, Van den Berg WB. Chondrocyte hypertrophy and osteoarthritis: Role in initiation and progression of cartilage degeneration? Osteoarthritis Cartilage. 2012;20(3):223-32. https://doi.org/10.1016/j.joca.2011.12.003

PMid:22178514

 Maxwell NJ, Ryan MB, Taunton JE, Gillies JH, Wong AD. Sonographically guided intratendinous injection of hyperosmolar dextrose to treat chronic tendinosis of the Achilles tendon: A pilot study. AJR Am J Roentgenol. 2007;189(4):215-20. https://doi. org/10.2214/AJR.06.1158

PMid:17885034

- Shakibaei M, Allaway D, Nebrich S, Mobasheri A. Botanical extracts from rosehip (*Rosa canina*), willow bark (*Salix alba*), and nettle leaf (*Urtica dioica*) suppress IL-1β-induced NF-κB activation in canine articular chondrocytes. Evid Based Complement Alternat Med. 2012;2012:509383. https://doi. org/10.1155/2012/509383
  - PMid:22474508
- Altman RD, Manjoo A, Fierlinger A, Niazi F, Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: A systematic review. BMC Musculoskelet Disord. 2015;16(1):321. https://doi.org/10.1186/ s12891-015-0775-z

PMid:26503103

- Monfort J, Pelletier JP, Garcia-Giralt N, Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis. 2008;67(6):735-40. https://doi.org/10.1136/ard.2006.068882 PMid:17644553
- Galli M, De Santis V, Tafuro L. Reliability of the ahlbaäck classification of knee osteoarthritis. Osteoarthritis Cartilage. 2003;11(8):580-4. https://doi.org/10.1016/ s1063-4584(03)00095-5 PMid:12880580
- Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SM, *et al.* OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. https://doi. org/10.1016/j.joca.2019.06.011 PMid:31278997
- de l'Escalopier N, Anract P, Biau D. Surgical treatments for osteoarthritis. Ann Phys Rehabil Med. 2016;59(3):227-33. https://doi.org/10.1016/j.rehab.2016.04.003
  PMid:27185463
- Fernández S, Córdoba M. Hyaluronic acid as capacitation inductor: Metabolic changes and membrane-associated adenylate cyclase regulation. Reprod Domest Anim Zuchthyg. 2014;49(6):941-6. https://doi.org/10.1111/rda.12410 PMid:25251082
- Lian C, Wang X, Qiu X, Wu Z, Gao B, Liu L, *et al*. Collagen Type II suppresses articular chondrocyte hypertrophy and osteoarthritis progression by promoting integrin β1-SMAD1 interaction. Bone Res. 2019;7(1):8. https://doi.org/10.1038/s41413-019-0046-y PMid:30854241
- Allemann F, Mizuno S, Eid K, Yates KE, Zaleske D, Glowacki J. Effects of hyaluronan on engineered articular cartilage extracellular matrix gene expression in 3-dimensional collagen scaffolds. J Biomed Mater Res. 2001;55(1):13-9. https://doi. org/10.1002/1097-4636(200104)55::1<13:aid-jbm20>3.0.co;2-g PMid:11426390
- Zheng Q, Zhou G, Morello R, Chen Y, Garcia-Rojas X, Lee B. Type X collagen gene regulation by Runx2 contributes directly to its hypertrophic chondrocyte-specific expression *in vivo*. J Cell Biol. 2003;162(5):833-42. https://doi.org/10.1083/ jcb.200211089

PMid:12952936

16. He Y, Manon-Jensen T, Arendt-Nielsen L, Petersen KK, Christiansen T, Samuels J, *et al.* Potential diagnostic value of a type X collagen neo-epitope biomarker for knee osteoarthritis. Osteoarthritis Cartilage. 2019;27(4):611-20. https://doi. org/10.1016/j.joca.2019.01.001 PMid:30654118

- He Y, Siebuhr AS, Brandt-Hansen NU, Wang J, Su D, Zheng Q, et al. Type X collagen levels are elevated in serum from human osteoarthritis patients and associated with biomarkers of cartilage degradation and inflammation. BMC Musculoskelet Disord. 2014;15(1):309. https://doi.org/10.1186/1471-2474-15-309 PMid:25245039
- 18. Amann E, Wolff P, Breel E, van Griensven M, Balmayor ER.

Hyaluronic acid facilitates chondrogenesis and matrix deposition of human adipose derived mesenchymal stem cells and human chondrocytes co-cultures. Acta Biomater. 2017;52:130-44. https://doi.org/10.1016/j.actbio.2017.01.064

PMid:28131943

 Girotto D, Urbani S, Brun P, Renier D, Barbucci R, Abatangelo G. Tissue-specific gene expression in chondrocytes grown on three-dimensional hyaluronic acid scaffolds. Biomaterials. 2003;24(19):3265-75. https://doi.org/10.1016/ s0142-9612(03)00160-1

PMid:12763454